| 5.59 -0.005 (-0.09%) | 03-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.53 | 1-year : | 6.54 |
| Resists | First : | 5.59 | Second : | 5.59 |
| Pivot price | 5.59 | |||
| Supports | First : | 5.59 | Second : | 4.65 |
| MAs | MA(5) : | 5.59 | MA(20) : | 5.59 |
| MA(100) : | 5.59 | MA(250) : | 5.05  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 83.1 | |||
| 52-week | High : | 5.61 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BDSI ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 5.61 - 5.63 | 5.63 - 5.66 |
| Low: | 5.52 - 5.56 | 5.56 - 5.58 |
| Close: | 5.54 - 5.59 | 5.59 - 5.63 |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Tue, 17 Jan 2023
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer - Business Wire
Sun, 08 May 2022
Document - SEC.gov
Mon, 14 Feb 2022
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal - GlobeNewswire
Wed, 17 Feb 2021
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021 - Yahoo Finance
Tue, 12 Mar 2019
BioDelivery Sciences - A Money Losing Opioid Company Founded By The Bankruptcy Experts - Seeking Alpha
Mon, 29 Oct 2018
BioDelivery Sciences Announces Changes to its Executive Leadership Team - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 99 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 68.8 (%) |
| Shares Short | 2,010 (K) |
| Shares Short P.Month | 1,690 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | -0.22 |
| EPS Est This Year | 0.11 |
| EPS Est Next Year | -0.64 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | 18.8 % |
| Operating Margin | 24.3 % |
| Return on Assets (ttm) | 10.4 % |
| Return on Equity (ttm) | 28.5 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 1.33 |
| Sales Per Share | 1.67 |
| EBITDA (p.s.) | 0.47 |
| Qtrly Earnings Growth | -24.9 % |
| Operating Cash Flow | 38 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | 23.29 |
| PEG Ratio | 0 |
| Price to Book value | 5.22 |
| Price to Sales | 3.33 |
| Price to Cash Flow | 14.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|